quinoxalines has been researched along with eapb0203 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El-Hajj, H; El-Sabban, ME; Hermine, O; Kfoury, Y; Lepelletier, Y; Moarbess, G | 1 |
| Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I | 1 |
| Bompart, J; Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; El Messaoudi, S; Gattacceca, F; Khier, S; Lafaille, F; Pinguet, F; Solassol, I | 1 |
| Banaigs, B; Bonnet, PA; Bressolle, FM; Doulain, PE; Enjalbal, C; Inguimbert, N; Lafaille, F; Masquefa, C | 1 |
| Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El Eit, R; Hmadi, R; Iskandarani, A; Mahon, FX; Nasr, R; Saliba, J | 1 |
| Bec, N; Constant, C; Courbet, A; Deleuze-Masquefa, C; El Messaoudi, S; Gattacceca, F; Khier, S; Larroque, C; Pugniere, M; Zghaib, Z | 1 |
| Bonnet, PA; Bressolle-Gomeni, FMM; Chouchou, A; Cuq, P; Deleuze-Masquéfa, C; Enjalbal, C; Marion, B; Roques, C | 1 |
7 other study(ies) available for quinoxalines and eapb0203
| Article | Year |
|---|---|
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Division; Cytochromes c; G2 Phase; Human T-lymphotropic virus 1; Humans; Imiquimod; Inflammation; Inhibitor of Apoptosis Proteins; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Activation; Lymphoma, T-Cell; Membrane Potential, Mitochondrial; NF-kappa B; Quinoxalines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2008 |
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
Topics: Animals; Antineoplastic Agents; Biotransformation; Blood Proteins; Dogs; Humans; Lymphoma, T-Cell; Melanoma; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Quinoxalines; Rats; Rats, Sprague-Dawley; Species Specificity; Spectrometry, Mass, Electrospray Ionization; Tissue Distribution | 2010 |
Characterization of a new anticancer agent, EAPB0203, and its main metabolites: nuclear magnetic resonance and liquid chromatography-mass spectrometry studies.
Topics: Animals; Antineoplastic Agents; Chromatography, Liquid; Deuterium Exchange Measurement; Dogs; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Oxygen; Quinoxalines; Rats | 2012 |
EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Pyrimidines; Quinoxalines | 2014 |
Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Colchicine; Computer Simulation; Humans; Models, Molecular; Molecular Docking Simulation; Protein Binding; Quinoxalines; Tubulin; Tubulin Modulators | 2017 |
Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Male; Mice; Mice, Inbred C57BL; Plasma; Quinoxalines; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2018 |